68 completed. 68 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 68 | Completed 68 |
| Phase 2 | 10 | Completed 10 |
Follow Hyperlipidemia: new trials by email Literature Review of Hyperlipidemia trials Research Report on Hyperlipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia AK102, Placebo - Hyperlipidemia | Phase 3 | Completed | Akeso | 246 | 2022-01-26 | 2025-03-06 |
| A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia AK102, Placebo - Hyperlipidemia | Phase 3 | Completed | Akeso | 122 | 2021-11-04 | 2025-02-28 |
| A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia AK102, Placebo - Hyperlipidemia | Phase 3 | Completed | Akeso | 464 | 2021-11-03 | 2025-03-06 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C K-877 0.1 mg tablet, Fenofibrate 200 mg capsule, Placebo tablet - Hyperlipidemia | Phase 3 | Completed | Kowa Company, Ltd. | 353 | 2021-09-17 | 2025-05-23 |
| Effect of Evolocumab on Coronary Atherosclerosis Evolocumab, 18F-NaF PET, CCTA - Cardiovascular Disease, Hyperlipidemia | Phase 3 | Completed | Cedars-Sinai Medical Center | 55 | 2019-03-19 | 2024-07-17 |
| Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia Temisartan+Amlodipine+Rosuvastatin (Combination drug), Temisartan+Amlodipine, Temisartan+Rosuvastatin - Hypertension, Hyperlipidemia | Phase 3 | Completed | Yuhan Corporation | 202 | 2017-04-11 | 2019-01-16 |
| The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production Insulin, Placebo - Hyperlipidemia | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 9 | 2016-04-14 | 2017-05-08 |
| Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 299 | 2015-06-01 | 2017-12-19 |
| Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 Atorvastatin10mg, Ezetimibe10mg, Atorvastatin10mg, Ezetimibe placebo, Atorvastatin20mg, Ezetimibe10mg - Hyperlipidemia | Phase 3 | Completed | Chong Kun Dang Pharmaceutical | 385 | 2015-03-01 | 2016-01-28 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 746 | 2014-10-28 | 2018-07-31 |
| Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia HGP0904, HGP0608, HGP0816 - Hypertension, Hyperlipidemia | Phase 3 | Completed | Hanmi Pharmaceutical Company Limited | 146 | 2014-07-01 | 2016-10-20 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins Bococizumab (PF-04950615;RN316), Atorvastatin, Placebo for Bococizumab (PF-04950615;RN316) - Hyperlipidemia | Phase 3 | Completed | Pfizer | 184 | 2014-06-01 | 2017-12-14 |
| Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe - Hyperlipidemia | Phase 3 | Completed | Amgen | 511 | 2013-12-10 | 2018-11-29 |
| Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia YH16410, Rosuvastatin, Telmisartan - Hyperlipidemia, Hypertension | Phase 3 | Completed | Yuhan Corporation | 210 | 2013-11-01 | 2014-07-08 |
| Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels Study Dietary Supplement (Prelipid 500 mg capsules), Placebo - Hyperlipidemia | Phase 3 | Completed | PreEmptive Meds, Pvt. Ltd | 180 | 2013-11-01 | 2015-05-15 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 2139 | 2013-10-29 | 2018-07-31 |
| Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events Bococizumab (PF-04950615;RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 711 | 2013-10-01 | 2017-05-17 |
| Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 Evolocumab, Placebo - Hyperlipidemia | Phase 3 | Completed | Amgen | 331 | 2013-02-07 | 2019-06-17 |
| Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 Evolocumab, Placebo to Evolocumab, Ezetimibe - Hyperlipidemia | Phase 3 | Completed | Amgen | 307 | 2013-01-24 | 2020-07-20 |
| Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 Evolocumab, Ezetimibe, Placebo to Evolocumab - Hyperlipidemia | Phase 3 | Completed | Amgen | 615 | 2013-01-21 | 2022-11-08 |
Showing 20 of 68. Sign in to see all of them.
Hyperlipidemias (68) · Hypertension (12) · Hypercholesterolemia (11) · Diabetes Mellitus (5) · Hyperlipoproteinemia Type II (5) · Diabetes Mellitus, Type 2 (4) · Hypertriglyceridemia (4) · Insulin Resistance (4) · Obesity (4) · HIV Infections (3) · Dyslipidemias (2) · Heart Diseases (2) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Coronary Disease (1)
Lipid Metabolism Disorders (68) · Metabolic Diseases (68) · Nutritional and Metabolic Diseases (68) · Dyslipidemias (66) · Cardiovascular Diseases (14) · Vascular Diseases (14) · Glucose Metabolism Disorders (11) · Endocrine System Diseases (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hyperinsulinism (5) · Hyperlipoproteinemias (5) · Lipid Metabolism, Inborn Errors (5) · Metabolism, Inborn Errors (5) · Body Weight (4)
Atorvastatin (16) · torcetrapib (7) · Ezetimibe (6) · Fenofibrate (6) · Simvastatin (6) · evolocumab (6) · bococizumab (5) · Rosuvastatin Calcium (3) · Atazanavir Sulfate (2) · Ezetimibe, Simvastatin Drug Combination (2) · MK-0524 (2) · Niacin (2) · Sitagliptin Phosphate (2) · Tea (2) · (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid (1)
Pfizer (12) · Amgen (5) · Merck Sharp & Dohme LLC (4) · Akeso (3) · Hanmi Pharmaceutical Company Limited (3) · Solvay Pharmaceuticals (3) · Abbott (2) · Chonbuk National University Hospital (2) · Organon and Co (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · University Health Network, Toronto (2) · Yuhan Corporation (2) · Cedars-Sinai Medical Center (1) · Chestnut Hill Health System (1) · Chong Kun Dang Pharmaceutical (1)
United States (29) · Canada (17) · South Korea (16) · France (10) · South Africa (9) · Australia (8) · Germany (8) · Netherlands (8) · Czechia (7) · United Kingdom (7) · Denmark (6) · Spain (6) · Taiwan (6) · Belgium (5) · China (5)
Abbas Delazar, PhD (1) · Ali Eskandari, MD (1) · Andrew R Zolopa (1) · Angel Brea, MD (1) · Barbara C Tilley, PhD (1) · Benjamin G Druss, MD MPH (1) · Byeong Hee Oh, M.D (1) · Chang-Gyu Park, Medicine (1) · Chang-Hsun Hsieh, M.D. (1) · Chih-Tsueng He, M.D. (1) · Chih-ching Wang, M.D. (1)
PMID 28304227, PMID 37994400, PMID 29685591, PMID 35277540, PMID 37658997, PMID 17387129, PMID 17387131, PMID 17407645, PMID 19029466, PMID 19029469, PMID 19328244, PMID 19576324, PMID 19952712, PMID 20019677, PMID 20228610, PMID 20435205, PMID 20645885, PMID 21291812, PMID 21613319, PMID 23431291, PMID 23816039, PMID 24584549, PMID 24614112, PMID 24961447, PMID 25057276, PMID 25084280, PMID 27039291, PMID 27742464, PMID 28751575, PMID 29150250, PMID 29673890, PMID 30400924, PMID 31145045, PMID 31529318, PMID 32937023, PMID 33078867, PMID 34486528, PMID 35471192, PMID 35654771, PMID 39098034, PMID 40178463, PMID 41832848
2005 (1), 2014 (1), R01MH070437 (1), R18DK067495 (1)